Literature DB >> 32571828

Rapidly Correcting Frameshift Mutations in the Mycobacterium tuberculosis orn Gene Produce Reversible Ethambutol Resistance and Small-Colony-Variant Morphology.

Hassan Safi1, Subramanya Lingaraju1, Shuyi Ma2, Seema Husain3, Mainul Hoque3, Patricia Soteropoulos3, Tige Rustad2, David R Sherman4, David Alland5.   

Abstract

We have identified a previously unknown mechanism of reversible high-level ethambutol (EMB) resistance in Mycobacterium tuberculosis that is caused by a reversible frameshift mutation in the M. tuberculosis orn gene. A frameshift mutation in orn produces the small-colony-variant (SCV) phenotype, but this mutation does not change the MICs of any drug for wild-type M. tuberculosis However, the same orn mutation in a low-level EMB-resistant double embB-aftA mutant (MIC = 8 μg/ml) produces an SCV with an EMB MIC of 32 μg/ml. Reversible resistance is indistinguishable from a drug-persistent phenotype, because further culture of these orn-embB-aftA SCV mutants results in rapid reversion of the orn frameshifts, reestablishing the correct orn open reading frame, returning the culture to normal colony size, and reversing the EMB MIC back to that (8 μg/ml) of the parental strain. Transcriptomic analysis of orn-embB-aftA mutants compared to wild-type M. tuberculosis identified a 27-fold relative increase in the expression of embC, which is a cellular target for EMB. Expression of embC in orn-embB-aftA mutants was also increased 5-fold compared to that in the parental embB-aftA mutant, whereas large-colony orn frameshift revertants of the orn-embB-aftA mutant had levels of embC expression similar to that of the parental embB-aftA strain. Reversible frameshift mutants may contribute to a reversible form of microbiological drug resistance in human tuberculosis.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  cas genes; drug resistance; embC; ethambutol; orn; reversible frameshift; small-colony variant

Mesh:

Substances:

Year:  2020        PMID: 32571828      PMCID: PMC7449195          DOI: 10.1128/AAC.00213-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus.

Authors:  Alexandre Pawlik; Guillaume Garnier; Mickael Orgeur; Pin Tong; Amanda Lohan; Fabien Le Chevalier; Guillaume Sapriel; Anne-Laure Roux; Kevin Conlon; Nadine Honoré; Marie-Agnès Dillies; Laurence Ma; Christiane Bouchier; Jean-Yves Coppée; Jean-Louis Gaillard; Stephen V Gordon; Brendan Loftus; Roland Brosch; Jean Louis Herrmann
Journal:  Mol Microbiol       Date:  2013-09-17       Impact factor: 3.501

2.  Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes.

Authors:  Hassan Safi; Subramanya Lingaraju; Anita Amin; Soyeon Kim; Marcus Jones; Michael Holmes; Michael McNeil; Scott N Peterson; Delphi Chatterjee; Robert Fleischmann; David Alland
Journal:  Nat Genet       Date:  2013-09-01       Impact factor: 38.330

3.  Molecular epidemiology of Mycobacterium tuberculosis strains isolated during a 3-year period (1993 to 1995) in Seville, Spain.

Authors:  H Safi; J Aznar; J C Palomares
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

4.  Characterization of NrnA homologs from Mycobacterium tuberculosis and Mycoplasma pneumoniae.

Authors:  Guillaume Postic; Antoine Danchin; Undine Mechold
Journal:  RNA       Date:  2011-11-23       Impact factor: 4.942

5.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

Review 6.  Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.

Authors:  Digby F Warner; Valerie Mizrahi
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

7.  IS6110 functions as a mobile, monocyte-activated promoter in Mycobacterium tuberculosis.

Authors:  Hassan Safi; Peter F Barnes; David L Lakey; Homayoun Shams; Buka Samten; Ramakrishna Vankayalapati; Susan T Howard
Journal:  Mol Microbiol       Date:  2004-05       Impact factor: 3.501

8.  Oligoribonuclease is the primary degradative enzyme for pGpG in Pseudomonas aeruginosa that is required for cyclic-di-GMP turnover.

Authors:  Mona W Orr; Gregory P Donaldson; Geoffrey B Severin; Jingxin Wang; Herman O Sintim; Christopher M Waters; Vincent T Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

9.  Why is long-term therapy required to cure tuberculosis?

Authors:  Lynn E Connolly; Paul H Edelstein; Lalita Ramakrishnan
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

10.  YtqI from Bacillus subtilis has both oligoribonuclease and pAp-phosphatase activity.

Authors:  Undine Mechold; Gang Fang; Saravuth Ngo; Vasily Ogryzko; Antoine Danchin
Journal:  Nucleic Acids Res       Date:  2007-06-22       Impact factor: 16.971

View more
  1 in total

1.  Distinctive roles of translesion polymerases DinB1 and DnaE2 in diversification of the mycobacterial genome through substitution and frameshift mutagenesis.

Authors:  Pierre Dupuy; Shreya Ghosh; Oyindamola Adefisayo; John Buglino; Stewart Shuman; Michael S Glickman
Journal:  Nat Commun       Date:  2022-08-02       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.